For this experiment the HDAC inhibitor Vorinostat, which is already approved for CTCL treatment (Mann et al., 2007), and the DOT1L inhibitor Pinometostat, which is in clinical trials for MLL-rearranged leukemia (Stein et al., 2018), were chosen. This evidence concerns the gene KMT2A and primary cutaneous T-cell non-Hodgkin lymphoma.